Material Event (Form 8-K)

Item 8.01 Other Events

Telomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer

Findings complement previously announced results in triple-negative breast cancer (TNBC) and prostate cancer models, highlighting Telomir-1's consistent impact on cancer cell survival pathways.

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) ("Telomir" or the "Company") announced new laboratory findings demonstrating that Telomir-1 reduced the survival of aggressive human pancreatic cancer (PANC-1) cells in vitro. Telomir-1 produced a concentration-dependent decrease in cell viability and mitochondrial activity, suggesting influence on cellular pathways related to energy metabolism and oxidative balance. These observations are consistent with previously reported data in triple-negative breast and prostate cancer models.

Similar to TNBC, Telomir-1's effects in pancreatic cancer cells were partially reversed by iron re-addition, indicating that iron-dependent processes contribute to the response. The incomplete rescue supports the interpretation that additional metabolic or epigenetic mechanisms are engaged in pancreatic models.

Telomir-1 has previously been shown to influence tumor suppressor genes and iron-dependent histone demethylases that are relevant to pancreatic cancer, including MASPIN (SERPINB5), RASSF1A, STAT1, KDM2B (FBXL10), and KDM6B (JMJD3). These genes and enzymes are known to govern DNA-methylation balance, oxidative stress response, and cellular energy regulation and are frequently dysregulated in aggressive tumor types.

The Company noted that pancreatic cancer is among the most difficult malignancies to treat, with a five-year survival rate of approximately 12 percent. Current standards of care-FOLFIRINOX and gemcitabine plus nab-paclitaxel-are limited by systemic toxicity and the rapid development of resistance. Telomir-1 is being evaluated preclinically for its ability to modulate epigenetic and metabolic regulators that contribute to cancer-cell survival and adaptation.

Telomir plans to expand its preclinical research to additional cancer models, including leukemia, and to initiate in vivo validation studies as part of its ongoing Investigational New Drug (IND) preparation.